Table S1 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Baseline characteristics of patients with RRD high-grade gliomas treated with immune-checkpoint inhibition (ICI) (n=75)
Table S1 from Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium | Synapse